Vantage logo

Biotech’s near-term key catalysts

Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.

Vantage logo

Novo’s Nash play takes shape

As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.